Over the last ten years, manufacturing output has grown by about 6% a year and is now worth more than $450 billion. But its ...

AKTX-102 is a first-in-class ADC that combines a novel CEACAM5-targeting antibody construct with Akari’s proprietary PH1 spliceosome-modulating payload, designed to deliver potent, differentiated ...